RxDoctor Payments Data

Varun Naragum, MD

Neuroradiology · Springfield, MANPI 1457628786

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (57.6%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. Microvention, Inc. accounts for 94.5% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2024 at $46,615 and has fallen 84.1% since, to $7,420 in 2025.

$75,266in general payments, 2019–2025

Across 148 payments — averaging $508.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Microvention, Inc.$71K
  • Balt USA, LLC$2K
  • Medtronic$1K
  • Johnson & Johnson$572
  • Imperative Care, Inc$233
  • Penumbra, Inc.$198
  • plus $215 from 2 others
$22,400in research payments, 2019–2025

Across 2 payments — averaging $11,200 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Microvention, Inc.$22K

What the payments were for

  • Consulting fees$14,90020%
  • Speaking & faculty fees$43,36358%
  • Travel & lodging$12,75017%
  • Food & beverage$4,2546%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Microvention, Inc.107$71,146
Balt USA, LLC7$1,806
Medtronic(2 entities)19$1,098
Johnson & Johnson7$572
Imperative Care, Inc3$233
Penumbra, Inc.2$198
Cook Medical LLC2$114
Stryker1$101

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$75,266 in reported general payments places this provider in the 80th percentile of 35 neuroradiology providers in Massachusetts.

See all neuroradiology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$215,694
Medicare patients
183
Services billed
910

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ClopidogrelClopidogrel Bisulfate75$1,553

Paid to pharmacies, not to this prescriber.

Other neuroradiology in Springfield

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →